Skip to Content

Tolbutamide Pregnancy and Breastfeeding Warnings

Tolbutamide is also known as: Orinase, Tol-Tab

Tolbutamide Pregnancy Warnings

This drug has been shown to be teratogenic in rats at dose 25 to 100 times the human dose. Isolated reports suggest harm in human pregnancy. This drug is expected to cross the placenta and may cause prolonged hypoglycemia in the neonate. There are no adequate and well controlled studies in pregnant women. Abnormal blood glucose levels during pregnancy have been associated with a higher incidence of congenital abnormalities. If diet alone is not adequate to maintain guideline recommended blood glucose levels, most experts suggest insulin as the drug of choice to achieve these ranges during pregnancy. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use should be avoided US FDA pregnancy category: C Comments: -This drug should not be used in the first trimester of pregnancy; women of childbearing potential should discuss adequate contraception with their healthcare provider. -Prolonged hypoglycemia has been reported in neonates born to mothers receiving a sulfonylurea at the time of delivery; if this drug is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date. -Most experts recommend insulin use during pregnancy to maintain blood glucose levels as close to normal as possible.

See references

Tolbutamide Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug Excreted into human milk: Yes Comments: There is a theoretical risk of hypoglycemia in the nursing infant; if diet alone is adequate for controlling blood glucose in the mother, insulin therapy should be considered.

Low amounts of this drug have been detected in human breastmilk. There is some information to suggest this may be too low to cause harm to the breastfed infant, but the potential for hypoglycemia exists. If used, it is advisable to monitor infant for hypoglycemia.

See references

References for pregnancy information

  1. "Product Information. Tolbutamide (TOLBUTamide)." Mylan Pharmaceuticals Inc, Morgantown, WV.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Tolbutamide (TOLBUTamide)." Mylan Pharmaceuticals Inc, Morgantown, WV.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.